Zydus Lifesciences gets 4 USFDA observations for Jarod Injectable facility

Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner

Edwards Lifesciences launches next-gen transcatheter heart valve in India

Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

Eris Lifesciences receives ANVISA approval for sterile injectable facility

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site